Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Pegylated Liposomal Doxorubicin as Initial Therapy for Multiple Myeloma
NCT00088855Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Oct 2006
- Modality
- Modified Peptides, Targeted Liposomes, Stealth (PEGylated) Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib and pegylated liposomal doxorubicin in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Complete Response + near-Complete Response rate at 18 weeks. Started Jun 2004; status: completed.
02
Drugs
bortezomibpegylated liposomal doxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00088855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00088855.